ATE205822T1 - Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren - Google Patents

Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren

Info

Publication number
ATE205822T1
ATE205822T1 AT97923625T AT97923625T ATE205822T1 AT E205822 T1 ATE205822 T1 AT E205822T1 AT 97923625 T AT97923625 T AT 97923625T AT 97923625 T AT97923625 T AT 97923625T AT E205822 T1 ATE205822 T1 AT E205822T1
Authority
AT
Austria
Prior art keywords
substituted
acid derivatives
matrix metalloprotease
metalloprotease inhibitors
arylbutyric acid
Prior art date
Application number
AT97923625T
Other languages
English (en)
Inventor
Harold C E Kluender
Brian R Dixon
David R Brittelli
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of ATE205822T1 publication Critical patent/ATE205822T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/84—Unsaturated compounds containing keto groups containing six membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97923625T 1996-05-15 1997-05-12 Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren ATE205822T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64768296A 1996-05-15 1996-05-15
PCT/US1997/007951 WO1997043237A1 (en) 1996-05-15 1997-05-12 Subsitute 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
ATE205822T1 true ATE205822T1 (de) 2001-10-15

Family

ID=24597888

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97923625T ATE205822T1 (de) 1996-05-15 1997-05-12 Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren

Country Status (21)

Country Link
EP (1) EP0923529B1 (de)
JP (1) JP3354941B2 (de)
CN (1) CN1225620A (de)
AR (1) AR007101A1 (de)
AT (1) ATE205822T1 (de)
AU (1) AU727468B2 (de)
BR (1) BR9709075A (de)
CA (1) CA2253795C (de)
CO (1) CO5011113A1 (de)
DE (1) DE69706874T2 (de)
ES (1) ES2160955T3 (de)
HR (1) HRP970247B1 (de)
ID (1) ID17326A (de)
MY (1) MY116903A (de)
PA (1) PA8429501A1 (de)
SV (1) SV1997000033A (de)
TN (1) TNSN97086A1 (de)
TW (1) TW442468B (de)
WO (1) WO1997043237A1 (de)
YU (1) YU18897A (de)
ZA (1) ZA974033B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288063B1 (en) 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
FR2832925B1 (fr) * 2001-12-03 2006-07-14 Lipha Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation
JP2012087113A (ja) * 2010-09-22 2012-05-10 Daicel Corp フェニル酢酸化合物
CN106661008A (zh) * 2014-04-03 2017-05-10 拜耳制药股份公司 用于治疗呼吸道疾病的2,5‑二取代的环戊烷甲酸
EP3126339A1 (de) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituierte cyclopentancarbonsäuren und ihre verwendung
CN106458938A (zh) 2014-04-03 2017-02-22 拜耳制药股份公司 手性2,5‑二取代的环戊烷甲酸衍生物及其用途
WO2015150364A1 (de) * 2014-04-03 2015-10-08 Bayer Pharma Aktiengesellschaft Substituierte benzotriazinonbutansäuren und ihre verwendung
US20170121315A1 (en) * 2014-06-12 2017-05-04 Bayer Pharma Aktiengesellschaft Heterobicyclically substituted 4-oxobutane acid derivatives and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE650081A (de) * 1963-07-03
FR2378741A1 (fr) * 1977-02-01 1978-08-25 Fabre Sa Pierre Acides garyl goxo isovaleriques doues de proprietes antiphlogistiques et antalgiques

Also Published As

Publication number Publication date
AU727468B2 (en) 2000-12-14
EP0923529A1 (de) 1999-06-23
AR007101A1 (es) 1999-10-13
BR9709075A (pt) 1999-08-03
ZA974033B (en) 1998-02-19
ES2160955T3 (es) 2001-11-16
JPH11510518A (ja) 1999-09-14
TW442468B (en) 2001-06-23
CN1225620A (zh) 1999-08-11
MY116903A (en) 2004-04-30
YU18897A (en) 1999-11-22
DE69706874D1 (en) 2001-10-25
HRP970247B1 (en) 2002-02-28
CA2253795A1 (en) 1997-11-20
JP3354941B2 (ja) 2002-12-09
DE69706874T2 (de) 2002-03-28
PA8429501A1 (es) 2000-05-24
CA2253795C (en) 2002-10-15
TNSN97086A1 (fr) 2005-03-15
HRP970247A2 (en) 1998-04-30
SV1997000033A (es) 1999-01-14
EP0923529B1 (de) 2001-09-19
WO1997043237A1 (en) 1997-11-20
ID17326A (id) 1997-12-18
AU2938997A (en) 1997-12-05
CO5011113A1 (es) 2001-02-28

Similar Documents

Publication Publication Date Title
DE69820906D1 (de) Hydroxamsäure-derivate als matrix metalloproteinaseinhibitoren
ATE226590T1 (de) Phosphinsäureamide als matrix metalloprotease inhibitoren
DE69725465D1 (de) 6-phenylpyridyl-2-amin-derivate verwendbar als nos-inhibitoren
NO972307D0 (no) Matriksmetallproteaseinhibitorer
DE69824199D1 (de) Lactamverbindungen als metalloprotease-inhibitoren
DK0925287T3 (da) Heterocykliske metalloproteaseinhibitorer
DK0923561T3 (da) Heterocykliske metalloproteaseinhibitorer
AU4201799A (en) Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
EE9900180A (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
ATE273288T1 (de) 2,3,4,5-tetrahydro-1h-(1,4)benzodiazepin-3- hydroxamsäure als matrix metalloproteinaseinhibitoren
FI973198A0 (fi) Silloitetut indolit matriisimetalloproteaasi-inhibiittoreina
BR9709902A (pt) Inibidores de metalo-proteinase de matriz
ID17291A (id) Penghambat matriks metalloprotease oleh asam biaril oksobutirat tersubstitusi
IL129035A0 (en) 3-Mercaptoacetylamino-1,5-substituted-2-oxo- azepan derivatives useful as inhibitors of matrix metalloproteinase
DK1047665T3 (da) Matrix metalloprotease inhibitorer
ATE205822T1 (de) Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren
ATE229497T1 (de) Substituierte phenethyl-derivate als matrx- metalloprotease-inhibitoren
ATE221065T1 (de) Amidinderivate als inhibitoren von no-synthase
HRP970246A2 (en) Substituted oxobutric acids as matrix metalloprotease inhibitors
NO965353D0 (no) 3-amino-2-okso-1-piperidineddiksyrederivater som enzyminhibitorer
SI0928291T1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties